Zacks Research Has Bearish Estimate for CORT FY2025 Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Equities research analysts at Zacks Research decreased their FY2025 earnings estimates for shares of Corcept Therapeutics in a research note issued on Wednesday, December 18th. Zacks Research analyst K. Das now forecasts that the biotechnology company will post earnings per share of $1.55 for the year, down from their prior forecast of $1.56. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.35 per share.

Several other equities analysts have also issued reports on the stock. Piper Sandler lifted their target price on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the company an “overweight” rating in a report on Wednesday, September 18th. StockNews.com lowered Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, November 25th. Sandler O’Neill reaffirmed a “buy” rating on shares of Corcept Therapeutics in a report on Friday, October 18th. Truist Financial boosted their target price on Corcept Therapeutics from $65.00 to $76.00 and gave the stock a “buy” rating in a research report on Monday, September 30th. Finally, HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Corcept Therapeutics in a report on Thursday, October 31st. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $65.25.

Corcept Therapeutics Price Performance

Shares of CORT stock opened at $52.17 on Monday. Corcept Therapeutics has a twelve month low of $20.84 and a twelve month high of $62.22. The stock has a market cap of $5.47 billion, a price-to-earnings ratio of 41.41 and a beta of 0.51. The business’s fifty day moving average is $54.05 and its 200 day moving average is $42.28. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.14. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The business had revenue of $182.55 million for the quarter, compared to analysts’ expectations of $171.97 million. During the same quarter in the previous year, the business posted $0.28 earnings per share. The firm’s revenue for the quarter was up 47.7% compared to the same quarter last year.

Institutional Investors Weigh In On Corcept Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Capital Performance Advisors LLP bought a new position in shares of Corcept Therapeutics in the third quarter worth approximately $25,000. Kathleen S. Wright Associates Inc. purchased a new position in shares of Corcept Therapeutics during the 3rd quarter valued at $36,000. GAMMA Investing LLC boosted its holdings in Corcept Therapeutics by 85.4% in the 3rd quarter. GAMMA Investing LLC now owns 2,490 shares of the biotechnology company’s stock worth $115,000 after buying an additional 1,147 shares during the period. KBC Group NV increased its stake in Corcept Therapeutics by 21.3% in the 3rd quarter. KBC Group NV now owns 2,822 shares of the biotechnology company’s stock worth $131,000 after buying an additional 496 shares in the last quarter. Finally, nVerses Capital LLC raised its holdings in Corcept Therapeutics by 62.5% during the second quarter. nVerses Capital LLC now owns 3,900 shares of the biotechnology company’s stock valued at $127,000 after acquiring an additional 1,500 shares during the period. 93.61% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Corcept Therapeutics

In related news, Director Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.88, for a total transaction of $131,736.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Joseph Douglas Lyon sold 1,411 shares of the business’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $56.72, for a total value of $80,031.92. Following the sale, the insider now directly owns 8,494 shares of the company’s stock, valued at $481,779.68. This represents a 14.25 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 26,811 shares of company stock worth $1,341,360 in the last quarter. Company insiders own 20.50% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.